| 000 | 01825 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514165334.0 | ||
| 264 | 0 | _c20040304 | |
| 008 | 200403s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/wnl.62.1.66 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReines, S A | |
| 245 | 0 | 0 |
_aRofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. _h[electronic resource] |
| 260 |
_bNeurology _cJan 2004 |
||
| 300 |
_a66-71 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects |
| 650 | 0 | 4 | _aApolipoprotein E4 |
| 650 | 0 | 4 |
_aApolipoproteins E _xgenetics |
| 650 | 0 | 4 | _aCyclooxygenase 2 |
| 650 | 0 | 4 | _aCyclooxygenase 2 Inhibitors |
| 650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoenzymes _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLactones _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMembrane Proteins |
| 650 | 0 | 4 | _aNeuropsychological Tests |
| 650 | 0 | 4 | _aProstaglandin-Endoperoxide Synthases |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSulfones |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aBlock, G A | |
| 700 | 1 | _aMorris, J C | |
| 700 | 1 | _aLiu, G | |
| 700 | 1 | _aNessly, M L | |
| 700 | 1 | _aLines, C R | |
| 700 | 1 | _aNorman, B A | |
| 700 | 1 | _aBaranak, C C | |
| 773 | 0 |
_tNeurology _gvol. 62 _gno. 1 _gp. 66-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/wnl.62.1.66 _zAvailable from publisher's website |
| 999 |
_c14446981 _d14446981 |
||